Dumping Syndrome
15
2
3
8
Key Insights
Highlights
Success Rate
89% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
6.7%
1 terminated out of 15 trials
88.9%
+2.4% vs benchmark
20%
3 trials in Phase 3/4
38%
3 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 8 completed trials
Clinical Trials (15)
Continuous Glucose Monitoring With iCan i3 in Post-Bariatric Patients With Late Dumping Syndrome
Dumping Syndrome and Esophageal Atresia
Comparing Dumping Symptoms and Quality of Life 6 Months After Sleeve Gastrectomy With or Without Transit Bipartition in Adults With Obesity
Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies
Fat Supplementation on Dumping Syndrome Related Symptoms After Gastric Surgery
Investigating the Impact of the SGLT2 Inhibitor Empagliflozin on Postprandial Hypoglycaemia After Gastric Bypass
SOMATULINE Autogel 90 mg IN DUMPING SYNDROME
Fat Supplementation on Dumping Syndrome Associated Symptoms
Gastrointestinal Nutrient Transit and Enteroendocrine Function After Upper Gastrointestinal Surgery
Impact of an Educational Personalized Clinical Support Device Preventive and a Referent Nurse in Surgery for Obesity
Gastrectomy, Eating Behaviour and GLP-1
Dumping Syndrome After Operation of Esophageal Atresia Type III
Metabolic Consequences of Gastrointestinal Surgery
Phase II Study Evaluating Efficacy, Safety and Pharmacokinetics of Pasireotide in Patients With Dumping Syndrome
Treatment of the Dumping Syndrome With Lanreotide Autogel®